55860-22-5 2-氯-N-(2-甲氧苯基)乙酰胺

危险等级为IRRITANT（刺激性），海关编码为2924297099

作为医药中间体或活性成分，用于相关药物研发与合成。

医药

合成路线 1（1. 合成：55860-22-5）

• 步骤: 向化合物A（0.5g，4.05mmol）的ACN（10.0mL）溶液中加入DIPEA（1.56mL，8.93mmol），然后在氩气氛下滴加化合物B（0.387mL，4.87mmol）。加完后，将反应物在室温下搅拌1小时。通过TLC监测反应完成。浓缩反应混合物，通过柱色谱（20％EtOAc：己烷）纯化，分离出所需化合物，为棕色固体（0.72g，89.05％）。
• 条件: With N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 1 h; Inert atmosphere
• 产率: 89.05%
• 1H NMR数据: (CDCl3, 400MHz) δ8.96 (s, 1H), 8.35 (dd, J = 1.6, 8.0Hz, 1H), 7.14-7.10 (m, 1H), 7.02-6.97 (m, 1H), 6.94-6.91 (m, 1H), 4.21 (s, 2H), 3.93 (s, 3H)

合成路线 2（以邻甲氧基苯胺和氯乙酰氯为原料）

• 步骤: 在氩气保护下，向邻甲氧基苯胺（0.5g，4.05mmol）的乙腈（10.0mL）溶液中加入N,N-二异丙基乙胺（DIPEA，1.56mL，8.93mmol），然后缓慢滴加氯乙酰氯（0.387mL，4.87mmol）。滴加完毕后，将反应混合物在室温下搅拌1小时。反应进程通过薄层色谱（TLC）监测。反应完成后，将反应混合物浓缩，并通过柱色谱法（洗脱剂：20％乙酸乙酯/己烷）进行纯化，得到目标化合物2-氯-N-(2-甲氧苯基)乙酰胺，为棕色固体（0.72g，收率89.05％）。
• 条件: 氩气保护；室温；1小时；TLC监测
• 产率: 89.05%
• 1H NMR数据: (CDCl3, 400MHz) δ8.96 (s, 1H), 8.35 (dd, J = 1.6, 8.0Hz, 1H), 7.14-7.10 (m, 1H), 7.02-6.97 (m, 1H), 6.94-6.91 (m, 1H), 4.21 (s, 2H), 3.93 (s, 3H) 参考文献: [1] Journal of Medicinal Chemistry, 2017, vol. 60, #14, p. 6289-6304；[2] Bioorganic and Medicinal Chemistry, 2014, vol. 22, #24, p. 6885-6892；[3] Farmaco, 2002, vol. 57, #3, p. 201-206；[4] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, #8, p. 1871-1879；[5] Bioorganic and Medicinal Chemistry, 2004, vol. 12, #13, p. 3471-3483；[6] Patent: US2003/232836, 2003, A1. Location in patent: Page 47；[7] Journal of the Indian Chemical Society, 1987, vol. 64, #11, p. 678-681；[8] Patent: US2008/221185, 2008, A1. Location in patent: Page/Page column 23-24；[9] Journal of the Iranian Chemical Society, 2018, vol. 15, #6, p. 1261-1277；[10] Archiv der Pharmazie, 2013, vol. 346, #11, p. 793-804；[11] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1986, vol. 25, p. 438-440；[12] Journal of Medicinal Chemistry, 2012, vol. 55, #14, p. 6391-6402；[13] Medicinal Chemistry Research, 2014, vol. 23, #3, p. 1290-1299；[14] Journal of the American Chemical Society, 1919, vol. 41, p. 1457；[15] Archiv der Pharmazie (Weinheim, Germany), 1915, vol. 253, p. 246；[16] Journal of Biological Chemistry, 1915, vol. 21, p. 150；[17] European Journal of Medicinal Chemistry, 1985, vol. 20, #2, p. 187-189；[18] Archiv der Pharmazie, 2004, vol. 337, #2, p. 105-111；[19] Journal of Organic Chemistry, 2009, vol. 74, #7, p. 2846-2849；[20] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, #9, p. 2705-2708；[21] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, #15, p. 4661-4664；[22] Chemical Biology and Drug Design, 2011, vol. 78, #2, p. 309-313；[23] Letters in Organic Chemistry, 2011, vol. 8, #10, p. 732-736；[24] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, #15, p. 5008-5012；[25] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2014, vol. 53, #6, p. 733-739；[26] Bioorganic and Medicinal Chemistry, 2015, vol. 23, #18, p. 6173-6184；[27] ChemMedChem, 2015, vol. 10, #9, p. 1489-1497；[28] Journal of Heterocyclic Chemistry, 2016, vol. 53, #5, p. 1595-1602；[29] European Journal of Medicinal Chemistry, 2016, vol. 123, p. 814-821；[30] Medicinal Chemistry, 2016, vol. 12, #7, p. 631-639；[31] Archiv der Pharmazie, 2016, vol. 349, #11, p. 864-880；[32] Bioorganic Chemistry, 2018, vol. 80, p. 288-295；[33] Journal of Heterocyclic Chemistry, 2018, vol. 55, #7, p. 1756-1764；[34] Chemical and Pharmaceutical Bulletin, 2017, vol. 65, #10, p. 950-958；[35] Chemistry and Biodiversity, 2018, [36] Bioorganic and Medicinal Chemistry Letters, 2019, vol. 29, #1, p. 22-27